Innovative mass spectrometry-based proteomics is a powerful tool for obtaining insights into disease-related cellular signaling pathways, biomarkers, and potential drug targets. This technology is being used to investigate phosphorylation of extracellular and intracellular proteins with the aim of improving early diagnosis and treatment of cancer and neurodegenerative diseases. In addition to phosphorylation studies, this technology can also be used to detect other PTMs including ubiquitylation. For example, E3 ubiquitin ligases represent a challenging, yet promising, class of proteins in drug discovery. In particular, combining the ligases with targeted protein degradation technology opens the door to developing new tools to study protein ubiquitinylation. To this end, the peptide K-ε-GG remnant affinity enrichment approach (PTMScan®) has been adapted for use with an automated liquid handling platform. This allows increased sensitivity and throughput while decreasing sample-to-sample variability in quantitative experiments. This approach has been successfully applied to the identification of downstream substrate protein candidates of disease-relevant E3 ubiquitin ligases. This webinar considers study design for label-free analysis, enrichment strategies, and data analysis involving both preclinical models and clinical samples with a focus on cancer.

 

During this webinar, participants will: